Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Tumor Immunology Publisher



Mahdavi Sharif P1, 2 ; Pastaki Khoshbin A1, 2 ; Nasrollahzadeh E2, 3 ; Keshavarzfathi M1, 2, 4 ; Rezaei N4, 5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
  4. 4. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Clinical Immunology Published:2022


Abstract

Cancer is the second leading cause of death worldwide. The immune system is a key player in the pathogenesis of cancer and contributes to the inhibition of transformed cells’ outgrowth as well as their progression. Immune components with anti-tumor properties are responsible for tumor eradication through major histocompatibility complex (MHC)-dependent and -independent mechanisms. There are also protumor and immunosuppressive components that support tumor outgrowth. Inspired by endogenous anti-tumor immunity, a variety of therapeutic approaches, including monoclonal antibodies, immune checkpoint inhibitors (ICIs), adoptive cell therapy, and vaccines, have been developed and evaluated for solid and hematologic malignancies. These immunotherapies have led to a significant improvement of overall survival (OS) in patients with cancer, and some of them are in use for cancer treatment in clinical practice. The combination of immunotherapy with other therapies is also of great importance in this way. Due to the clinical importance of tumor immunology, in this chapter, we will first discuss the basic cancer immunobiology focusing on the interaction of the immune system and transformed cells to inhibit or foster cancer progression and then provide an updated review on the application of immunotherapy for different cancer types, combination therapy, and immunoediting after other therapeutic approaches. © 2023 Elsevier Inc. All rights reserved.
Related Docs
View other Related Docs
1. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
2. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
3. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
4. Pro-Tumorigenic Functions of Macrophages at the Primary, Invasive and Metastatic Tumor Site, Cancer Immunology# Immunotherapy (2020)
5. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
6. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
7. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
8. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (116)
Hamid Reza Mirzaei (29)
Other Related Docs
9. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
10. Immune Checkpoint Inhibition for Pancreatic Cancer, Acta Medica Iranica (2023)
11. A Narrative Review of Tumor-Associated Macrophages in Lung Cancer: Regulation of Macrophage Polarization and Therapeutic Implications, Translational Lung Cancer Research (2021)
12. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
13. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
14. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
15. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)
16. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
17. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)
18. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
19. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
20. Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond, Archivum Immunologiae et Therapiae Experimentalis (2019)
21. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)
22. The Role of Myeloid-Derived Suppressor Cells in Lung Cancer and Targeted Immunotherapies, Expert Review of Anticancer Therapy (2022)
23. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
24. The Pro-Tumorigenic Responses in Metastatic Niches: An Immunological Perspective, Clinical and Translational Oncology (2023)
25. Clinical Potential of Pd-1/Pd-L1 Blockade Therapy for Renal Cell Carcinoma (Rcc): A Rapidly Evolving Strategy, Cancer Cell International (2022)
26. The Immunobiology of Myeloid-Derived Suppressor Cells in Cancer, Tumor Biology (2016)
27. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms, Vaccines (2022)
28. Immune Checkpoint Inhibitors Therapy As the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape, Critical Reviews in Oncology/Hematology (2024)
29. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
30. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
31. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
32. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
33. Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma: A Systematic Review and Meta-Analysis of Efficacy and Review of Characteristics, Expert Review of Anticancer Therapy (2023)
34. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
35. A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe?, Translational Oncology (2023)
36. Adverse Events Following Administration of Anti-Ctla4 Antibody Ipilimumab, Frontiers in Oncology (2021)
37. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
38. Chemotherapy: A Double-Edged Sword in Cancer Treatment, Cancer Immunology# Immunotherapy (2022)
39. Recent Advances in Non-Small Cell Lung Cancer Targeted Therapy; an Update Review, Cancer Cell International (2023)
40. The Tale of Tils in Breast Cancer: A Report From the International Immuno-Oncology Biomarker Working Group, npj Breast Cancer (2021)
41. The Roles of Metabolic Profiles and Intracellular Signaling Pathways of Tumor Microenvironment Cells in Angiogenesis of Solid Tumors, Cell Communication and Signaling (2022)
42. The Evolving Landscape of Predictive Biomarkers in Immuno-Oncology With a Focus on Spatial Technologies, Clinical and Translational Immunology (2020)
43. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
44. The Complex Role of Macrophages in Pancreatic Cancer Tumor Microenvironment: A Review on Cancer Progression and Potential Therapeutic Targets, Discover Oncology (2024)
45. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
46. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
47. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
48. Immune Landscape of Hepatocellular Carcinoma: From Dysregulation of the Immune Responses to the Potential Immunotherapies, Cell Biochemistry and Function (2024)
49. Neurological Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy, Expert Review of Clinical Immunology (2023)
50. The Roles of Cd4+ T-Cells in Tumor Immunity, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)